LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES

Long-acting drug delivery has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level.

Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. The long-acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, better medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. In addition, long acting drug delivery formulations can improve the chemical stability, solubility and polymorphic transformation issues of the active pharmaceutical ingredients.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/long-acting-

Lately, many technologies are being explored to develop long-acting drugs in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The long-acting drug delivery technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. Long-acting formulations are more patient compliant, in terms of sharp reduction in the dosing regimen. These drugs are administered infrequently (ranging from once weekly to yearly) owing to the prolonged drug release after a single shot.

The technological advancements for the long-acting profile of the drugs (small molecules, peptides, biologics) have led to the rise in number of novel therapeutics in the market along with the growing number of long-acting molecules in the clinical development pipeline. Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. Further, the pharmaceutical industry is extensively focusing on the development of long-acting injectables for protein-based drugs and multidrug therapies. Moreover, the potential of long acting injectables is being explored in several debilitating chronic diseases, such as Alzheimer’s, Parkinson’s disease, blindness and HIV. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on the stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome.

For additional details, please visit
https://www.rootsanalysis.com/....reports/long-acting- or email [email protected]

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

 

www.rootsanalysis.com

Request Sample - Long-Acting Drug Delivery Market | Industry Analysis | Market Size | 2035

Long-acting drug delivery technologies, driven by presence of nearly 100 companies, is anticipated to grow at 13% CAGR

TIL-BASED THERAPY: AN INNOVATIVE WAY TO TREAT SOLID TUMORS

Modified tumor-infiltrating lymphocytes (TIL)-based interventions have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects.

Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL therapies . Their tumor-cell killing efficiency is attributed to the fact that they are pre-sensitized to cancer specific antigens. Additionally, this emerging class of biologics is believed to possess the potential to cater to the unmet pharmacological needs, across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/til-therapie

Over the years, various studies have validated the successful use of tumor-infiltrating lymphocytes (TILs) in treating patients diagnosed with refractory diseases. TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, NK cells and macrophages isolated from the tumor. These lymphocytes selectively mediate the elimination of tumor cells. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TIL-based therapy market is likely to witness significant growth in the foreseen future. With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 40% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by therapies being developed to target melanoma and head and neck carcinoma. Additionally, close to 90% of the market is anticipated to be captured by players based in North America and Europe, in 2035. Overall, we are led to believe that the global TIL therapies market is poised to witness significant growth in the foreseen future.

For additional details, please visit
https://www.rootsanalysis.com/....reports/til-therapie or email [email protected]

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

DIGITAL THERAPEUTICS - THE INCREASING REGULATORY SUPPORT HAS FACILITATED THE ESTABLISHMENT OF A STANDARD DEVELOPMENTAL PATHWAY FOR THESE SOLUTIONS

Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions.

Digital Therapeutics, popularly known as DTx, represent a digital health solution which delivers medical interventions directly to the patients in order to treat, manage and prevent a disease. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing motivational support and inculcating healthy lifestyle changes.
Several organizations have undertaken diverse initiatives in the field of digital therapeutics to support its growth as a new frontier in the healthcare sector. A number of organizations focused on effectively monitoring and promoting the potential of digital therapeutics to be used as a part of strategies to improve the population health have also been established. These organizations include:
 Digital Therapeutics Alliance (DTA)
 Personal Connected Health (PCH) Alliance
 Centers for Disease Control and Prevention (CDC)
 Health Insurance Portability and Accountability Act (HIPAA)
 National Health Service (NHS)
 United States Food and Drug Administration (USFDA)

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/208/request-

Given the current activity in this domain and the growing demand for such solutions, the digital therapeutics market is likely to grow at a healthy pace over the next decade. Traversing a digital therapeutic from the R&D stage to the market is a long process. The various developmental stages involved in this process have been discussed in detail in the following sections.
 Discovery and Preclinical Phase: The discovery phase involves the identification of a novel digital therapeutic intervention. At this stage, researchers publish their work in academic journals and continue to investigate the potential applications of their digital solutions in disease treatment / management.

 Clinical Trials and Validation: This phase involves the conduct of proper clinical trials to validate the claims made by a digital therapeutic solution provider, and to evaluate its potential in a real-world setting. It includes testing of the digital therapeutics software / hardware on a specific patient population. In case of clinical studies, health outcomes are measured and tracked through data driven insights provided by the software. Disease specific improvements (post application / implementation of the intervention) are also tracked to evaluate the performance of a product. There are multiple challenges associated with conducting clinical trials for digital therapeutics. Firstly, technologies are known to change rapidly and there is a very high probability for a software to undergo upgrades / improvements over the duration of a clinical trial. As a result, there are technical issues in storing and updating patient data. Secondly, digital interventions cannot be studied in a double-blind manner, because the investigator is always aware of whether a trial subject is in the control group or being treated with the intervention under evaluation. Finally, at present, there is less structure and guidelines available, and as a result meaningful and conclusive insights are difficult to be drawn from such trials.

 Negotiations with Insurance Providers / Payers: Post the successful completion of clinical studies, developer companies generally tend to avail reimbursement opportunities for their products in order to promote the use of their proprietary solutions and provide financial benefits to patients / consumers. As is the case with pharmacological interventions, reimbursement plans for these products can be achieved based on the outcomes of clinical trials and depending on the USFDA’s (or the concerned regulatory authority of a particular region) clearance. A number of health insurance providers, such as Medicare and Humana, are actively working to include digital therapeutics as a part of health insurance coverage plans for patients suffering from chronic diseases.

 Distribution and Marketing: The pharmaceutical and medical device distribution / marketing system is an established network with well-defined channels through which manufacturers can reach the end-users of their products. Product developers in this domain are presently looking to create a distribution network to sell their offerings in the market via both B2B (healthcare providers, regulators and payers) and B2C (customer) models.

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen or email [email protected]

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

 

www.rootsanalysis.com

Request Sample - Digital Therapeutics Market | Industry Analysis | Market Size | 2035

Driven by the growing demand for digital and remote health solutions, the digital therapeutics market is likely to witness 20% annual growth in the short to mid term

AI-BASED DIGITAL PATHOLOGY GAINS INTEREST DUE TO AUTOMATION, DIGITIZATION OF HEALTHCARE, SHORTAGE OF PATHOLOGISTS, AND INCREASED DEMAND FOR PATHOLOGY SERVICES

In recent years, advancements in technology and emphasis on precision medicine have recently paved the path for the development of artificial intelligence (AI) based digital pathology techniques for quantitative and qualitative assessment of samples.

Specifically, the process of AI-based digital pathology allows scanning of slides via computer monitors, by replacing the conventional microscopic approaches. Further, by converting glass slides to images, samples can be transmitted from diagnostic centers to pathologists within a fraction of time. Considering the rising popularity and demand for such solutions in the healthcare and research industry, and the ongoing efforts of AI-powered digital pathology solution providers / AI pathology solution providers to further improve / expand their respective portfolios, we believe that the AI-based digital pathology market / AI Pathology Market is likely to evolve at a steady pace, till 2035.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/ai-based-dig

The steps involved in the usual workflow of AI-based digital pathology process.

 Preparation of Tissue Sample: This process is very similar to the conventional approach. A pathologist examines a biopsy to determine its color, size and consistency. At this point, the specialist can detect symptoms of malignancy and select which areas of a specimen should be inspected under the microscope. Further, the chosen region is prepared by following multi-step processes, such as treatment of the tissue with chemicals in order to maintain its structure, mounting the specimen on a glass slide, staining to improve contrast and protecting the tissue with coverslips.

 Converting into Virtual Sample / Whole slide imaging (WSI): WSI or virtual microscopy is a technique that is used to enable digital pathology. Its central component, which is a WSI scanner, captures a picture of the glass slide and generates a precise electronic replica known as a virtual slide. It is worth noting that virtual slides, unlike glass slides, are easy to replicate, save, categorize and distribute. Furthermore, they may be linked to electronic health records, thereby, providing a complete picture of a patient's health.

 Saving a Virtual Slide: The scanner pre-processes the virtual slide automatically and stores it to on-premises or cloud storage. In order to minimize the file size, a compression approach is frequently employed before saving the slide.

 Viewing and Editing of Slide: In the digital process, instead of using a traditional microscope, a pathologist uses a computer display to analyze enlarged tissue samples. A slide viewing and management software is used to zoom out a tissue segment and observe its smallest features. In addition, this software allows the pathologist to view the slide from different angles, add annotations and even compare multiple images at one time.

 Sharing Data: Using specialized digital pathology software applications, slides are converted to an electronic format, thereby, allowing them to be exchanged using the internet. These slides can be shared to gain a second opinion, as well as with patients, research facilities and other stakeholders.

 Reporting Results: Some image viewing systems provide reporting capabilities. However, this work is often accomplished by enabling interaction with the laboratory information or laboratory information management system (LIS/LIMS) and hospital information system (HIS).

The digital revolution of pathology is projected to accelerate in the coming years, considering multiple growth drivers, including growing number of laboratories adopting high throughput digital scanning and software technologies to assist diagnostic practice. In addition, factors, including shortage of skilled pathologists in remote areas, increasing pathology workloads due to ageing populations, higher rate of cancer screening programs, rising complexity of pathology testing and time constraints, and requirement for pathology labs to outsource expertise in the field, also contributes significantly towards the need for AI-based digital pathology solutions.

For additional details, please visit
https://www.rootsanalysis.com/....reports/ai-based-dig or email [email protected]

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

 

www.rootsanalysis.com

Request Sample - AI-based Digital Pathology Market | Industry Analysis | Market Size | 2035

Driven by the rise in demand for digital pathology solutions, we anticipate AI pathology market to grow at an annualized rate of ~8% till 2035

The dental 3D printing market is anticipated to grow at a CAGR of 15.1% during the period 2023-2035, claims Roots Analysis

The growing burden of dental diseases and the challenges associated with the conventional dental product manufacturing methods has significantly increased the adoption of 3D printing in the dental industry

Roots Analysis has announced the addition of “Dental 3D Printing Market, 2023 – 2035” report to its list of offerings.

The popularity of 3D printing technology within the dental industry can be attributed to its ability to print high quality / accurate dental products, including crowns, bridges, dentures, dental implants and surgical guides. Driven by the overall growth of the additive manufacturing (3D printing) industry, and wide adoption of 3D printers in the dental sector, the dental 3D printing market is anticipated to witness a steady growth in the foreseen future.


Key Market Insights

Currently, around 230 dental 3D printers are available for use across wide range of applications
Majority (38%) of the dental 3D printers use digital light processing (DLP) as printing technology, followed by those using stereolithography (SLA) technology (21%). Further, close to 75% of the dental 3D printers can produce crowns / bridges / dentures, followed by those manufacturing working models (61%) and surgical guides (59%). It is worth highlighting that around 55% of the dental 3D printers currently available in the market have a price range below USD 10,000.

More than 80 companies claim to offer dental 3D printers, across the world
Majority of the firms (46%) engaged in this domain are mid-sized players, followed by large (32%) and small firms (22%). It is worth highlighting that, more than 50% of the companies in this domain have been established post-2010. Further, around 85% of the dental 3D printer manufacturers are based in Asia-Pacific and Europe, followed by those headquartered in North America (16%), and within the Asia-Pacific region, China emerged as the most prominent hub, featuring the presence of maximum number of players (62%).

Partnership activity has grown at an annualized rate of over 70%, between 2018-2022
Maximum number of partnerships were established in 2021 (56) and 2022 (44), indicating the recent surge in the partnership activity in this domain. Majority of these (26%) were product integration agreements. Further, most of the intercontinental as well as intracontinental deals have been inked by the players based in North America.

500+ patents related to dental 3D printing have been granted / filed between 2019 and 2022
R&D activity related to dental 3D printing is largely concentrated in Asia-Pacific, considering the fact that 50% of the total number of patents were filed in this region. It is worth highlighting that, within the Asia-Pacific region, China emerged as the most active country with ~230 filed patents. In addition, most of the patents in this domain are patent applications (65%).

North America and Europe are anticipated to capture around 75% share of the market by 2035
In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (with CAGR of 16.3%) in the long term. Further, in 2035, based on type of printing technology, majority of the revenue share (64%) of the overall market is likely to be driven by vat polymerization technology. Further, in terms of application area, prosthodontics currently holds largest share (55%) of the market.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/dental-3d-pr

Key Questions Answered
 How is 3D printing used in the dental industry?
 How many dental 3D printers are currently available in the market?
 Which 3D printers are best for dentistry?
 What is the growth rate of the dental 3D printing market?
 Which region captures the largest share of the dental 3D printing market?
 Which printing technology is widely used in the dental 3D printers?
 Which application area currently holds the largest share in the dental 3D printing market?
 What are the partnerships and collaborations trend in the dental 3D printing domain?
 How many patents have been filed / granted related to dental 3D printing in the recent years?

The financial opportunity within the dental 3D printing market has been analyzed across the following segments:
 Type of Printing Technology
 VAT Polymerization Technology
 Powder Bed Fusion Technology
 Polyjet Technology
 Metal Extrusion Technology
 Other Technologies

 Application Area
 Prosthodontics
 Orthodontics
 Dental Implants
 Other Applications

 Type of Printing Material
 Resins
 Plastics
 Metals
 Metals
 Other Material

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

The research also includes detailed profiles of key players (listed below) featuring a brief overview of the company, details related to dental 3D printer portfolio, recent developments, and an informed future outlook.
 3D Systems
 Asiga
 BEGO
 Carbon
 Digital Wax Systems (DWS)
 Formlabs
 Prodways
 Rapid Shape
 SprintRay
 Stratasys

For additional details, please visit
https://www.rootsanalysis.com/....reports/dental-3d-pr
or email [email protected]

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. Medical Devices Contract Research Organizations Market (3rd Edition): Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.



Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]